Samimi Mozhgan Aalam, Mirkheshti Nooshin, Pazouki Abdolreza
Assistant Professor, Minimally Invasive Surgery Research Center, Iran University Of Medical Science, Tehran, Iran.
Medical Doctor, East Sage Research Corporation, Isfahan Science and Technology Town, Isfahan, Iran.
Int J Hematol Oncol Stem Cell Res. 2014;8(1):5-8.
Osteosarcoma is the most common primary bone tumor in children and young adults and appropriate chemotherapy can increase limb sparing and overall survival. Yet, the toxicity of chemotherapy regimens including MTX can be life threatening. Therefore; we tried another chemotherapy regimen for these patients.
We investigated 15 patients aged 15 to 40 years old and used continuous infusion of cisplatin, doxorubicin intermittently with ifosfamide, doxorubicin as neoadjuvant chemotherapy. Percent of necrosis and toxicities was recorded for each patient.
Out of 15 patients investigated, 13 were males and 2 females. Tumor necrosis≥ 90% (defined as good necrosis) was observed in 60% of patients. 26.7% of the patients showed leucopenia grade three or four, 26.7% had anemia grade three or four, and 20% showed thrombocytopenia grade three or four.
The above chemotherapy regimen can cause as good necrosis as the chemotherapy regimens including high dose of MTX with reduced toxicity and less nursing cares and laboratory tests. Of course small sample size limits extension of our result to all patients but trying this regimen is recommended in more patients to see more reliable results.
骨肉瘤是儿童和青年中最常见的原发性骨肿瘤，适当的化疗可提高保肢率和总生存率。然而，包括甲氨蝶呤（MTX）在内的化疗方案的毒性可能危及生命。因此，我们为这些患者尝试了另一种化疗方案。
我们研究了15名年龄在15至40岁之间的患者，采用顺铂持续输注、阿霉素与异环磷酰胺间歇使用、阿霉素作为新辅助化疗。记录每名患者的坏死率和毒性。
在研究的15名患者中，13名男性，2名女性。60%的患者观察到肿瘤坏死≥90%（定义为良好坏死）。26.7%的患者出现三或四级白细胞减少，26.7%的患者出现三或四级贫血，20%的患者出现三或四级血小板减少。
上述化疗方案可产生与包括高剂量MTX在内的化疗方案同样好的坏死效果，且毒性降低，护理和实验室检查减少。当然，小样本量限制了我们的结果推广至所有患者，但建议在更多患者中尝试该方案以获得更可靠的结果。
